dc.contributor.author | Berman, Adi Yedidah | |
dc.date.accessioned | 2018-10-16T19:02:34Z | |
dc.date.available | 2018-10-16T19:02:34Z | |
dc.date.issued | 2015-12-16 | |
dc.identifier.uri | https://hdl.handle.net/20.500.12202/3971 | |
dc.identifier.uri | https://ezproxy.yu.edu/login?url=https://repository.yu.edu/handle/20.500.12202/3971 | |
dc.description | The file is restricted for YU community access only. | |
dc.description.abstract | Drug resistance is currently one of the most critical health concerns. While the exact
mechanisms of drug resistance remain unknown, certain aspects of it can be revealed by
studying drug resistance from two perspectives: the microbe and the human cell. Two
diseases that are notoriously difficult to treat due to the development of resistance
mechanisms are malaria and estrogen receptor α (ERα)-positive breast cancer. The malaria
parasite of the genus Plasmodium has developed several genetic mutations which allow it to
circumvent the therapeutic actions of current antimalarials, indicating the importance of
identifying novel drug targets. Plasmodium vivax Equilibrative Nucleoside Transporter 1
(PvENT1) has been identified as a potential drug target, but the potential of resistant
mechanisms emerging to PvENT1 inhibitors through genetic mutations has yet to be
sufficiently determined. Characterization of PvENT1 single nucleotide polymorphisms
(SNPs) showed that overall, the transporter’s function remains unchanged, indicating the
potential success of PvENT1 inhibitors. Additionally, the development of endocrine therapy
resistance offers a different perspective of drug resistance. It is found to occur in part due to
the molecular cross-talk between the ERα and growth factor signaling pathways, such as the
mammalian Target of Rapamycin (mTOR) pathway. Combination treatments using
endocrine therapy and mTOR inhibitors have been proposed to prevent the emergence of
endocrine therapy resistance. The discovery of a direct link between the ERα and mTOR
pathways, the binding of ERα to regulatory associated protein of mTOR (raptor), provides a
new, viable target for mTOR inhibitors administered in combination with endocrine therapy.
The findings presented in this work are therefore important steps in the ongoing effort to
successfully identify new treatments for these two diseases. Moreover, this work expounds
3
upon the importance of furthering scientific understanding of drug resistance mechanisms,
and of identifying novel treatments that would combat and prevent the development of drug
resistance. | en_US |
dc.description.sponsorship | S. Daniel Abraham Honors Program | en_US |
dc.publisher | Stern College for Women | en_US |
dc.rights | Attribution-NonCommercial-NoDerivs 3.0 United States | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/3.0/us/ | * |
dc.subject | Drug resistance in cancer cells | en_US |
dc.subject | Malaria -- Treatment | en_US |
dc.subject | Breast -- Cancer -- Treatment | en_US |
dc.title | An Analysis of Drug Resistance Mechanisms in Plasmodium vivax Malaria and ERα-Positive Breast Cancer and Their Implications for the Prevention Drug Resistance in Future Therapeutic Development | en_US |
dc.type | Thesis | en_US |